uploads/2018/08/Chart-007-1.jpg

A Look at Eli Lilly’s Neuroscience Products in Q2 2018

By

Updated

Neuroscience products

Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes neuroscience products such as Cymbalta, Strattera, and Zyprexa.

The overall sales for neuroscience products fell in the second quarter following lower sales of the majority of drugs from the neuroscience portfolio.

The chart above shows the revenues for LLY’s neuroscience products since the first quarter of 2017.

Article continues below advertisement

Cymbalta

Cymbalta is an antidepressant drug. Cymbalta reported a 12% YoY fall in revenue to $181.9 million in the second quarter compared to $206.6 million in the second quarter of 2017. The fall was driven by lower US sales, and it was partially offset by strong international sales. The company’s US sales fell to $12.6 million, while its sales from international markets increased to $169.4 million during the quarter.

Strattera

Strattera is a drug for the treatment of attention deficit disorder and hyperactivity disorders. Strattera reported a 39% YoY fall in revenue to $114.2 million in the second quarter compared to $186.6 million in the second quarter of 2017. The fall was driven by lower US sales, and it was partially offset by strong international sales. Its US sales fell to $16.9 million, while its international sales rose to $97.3 million in the quarter.

Zyprexa

Zyprexa is an antipsychotic drug. Zyprexa reported a 9% fall in YoY revenue to $128.0 million in the second quarter, a fall of 9% YoY compared to $140.8 million in the second quarter of 2017. The fall was driven by lower sales globally. Its US sales fell to $11.8 million, while its international sales fell to $116.2 million in the quarter.

The iShares Core High Dividend ETF (HDV) holds 1.7% of its total investments in Eli Lilly (LLY), 1.9% in Bristol-Myers Squibb (BMY), 3.7% in Merck & Co. (MRK), and 6.8% in Johnson & Johnson (JNJ).

Advertisement

More From Market Realist